Schering GMP problems hurt K-Dur
Executive Summary
Sales of extended-release potassium chloride brand K-Dur decline 65% in second quarter to $19 mil., Schering-Plough reports. The product was among those affected by manufacturing and trade stocking issues, company says. FDA's June 5 FD-483 inspection report for Schering's Las Piedras, Puerto Rico facility includes numerous observations related to K-Dur manufacturing